Were Kerry Wentworth’s Nuvation Bio (NUVB) share sales pre-planned under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that Kerry Wentworth’s 36,750-share sale was made pursuant to a Rule 10b5-1 trading plan dated December 4, 2025. Such plans pre-arrange trading activity, helping separate routine portfolio management from discretionary market-timing decisions by insiders.

Nuvation Bio (NASDAQ: NUVB) CRO exercises options, sells shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised options and sold shares in a planned transaction. On April 17, 2026, Wentworth exercised options to acquire 36,750 shares of Class A common stock at $2.93 per share, then sold 36,750 shares in open-market trades at a weighted-average price of $5.0144 under a Rule 10b5-1 trading plan. After these transactions, Wentworth directly owns 53,000 shares of Nuvation Bio Class A common stock.

Insider Trade Summary 10b5-1

Net Seller: 36,750 shares ($184,279)

Net Sell 3 txns

Insider Wentworth Kerry

Role CHIEF REGULATORY OFFICER

Sold 36,750 shs ($184K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	36,750	$0.00	--
Exercise	Class A Common Stock	36,750	$2.93	$108K
Sale	Class A Common Stock	36,750	$5.0144	$184K

Holdings After Transaction: Stock Option (Right to Buy) — 215,250 shares (Direct, null); Class A Common Stock — 89,750 shares (Direct, null)

Footnotes (1)

Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.05. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

Key Figures

Shares sold: 36,750 shares Sale price (weighted-average): $5.0144 per share Sale price range: $5.00–$5.05 per share +5 more

8 metrics

Shares sold 36,750 shares Class A common stock sold in open market on April 17, 2026

Sale price (weighted-average) $5.0144 per share Open-market sale of 36,750 shares on April 17, 2026

Sale price range $5.00–$5.05 per share Price range for 36,750 shares sold by Kerry Wentworth

Options exercised 36,750 shares Stock options exercised into Class A common stock

Exercise price $2.93 per share Exercise price for stock options exercised on April 17, 2026

Shares owned after 53,000 shares Direct Class A common stock holdings after transactions

Option expiration August 28, 2032 Expiration date for the stock option grant

Initial vesting date August 29, 2023 25% of option vests one year after August 29, 2022

Key Terms

Rule 10b5-1 plan, weighted-average sales price, Stock Option (Right to Buy), Class A Common Stock, +1 more

5 terms

Rule 10b5-1 plan regulatory

"Shares sold pursuant to a 10b5-1 plan dated December 4, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average sales price financial

"Price reported is a weighted-average sales price."

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Class A Common Stock financial

"security_title": "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vests as to 25% financial

"Option vests as to 25% on the one year anniversary"

Form 4 Insider Transactions: What Each Field Means →

04/21/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wentworth Kerry

(Last)

(First)

(Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF REGULATORY OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	04/17/2026		M		36,750	A	$2.93	89,750	D
Class A Common Stock	04/17/2026		S⁽¹⁾		36,750	D	$5.0144⁽²⁾	53,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.93	04/17/2026		M			36,750	⁽³⁾	08/28/2032	Class A Common Stock	36,750	$0	215,250	D

Explanation of Responses:

1. Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.

2. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.05. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

3. Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Nuvation Bio (NUVB) executive Kerry Wentworth do in this Form 4?

Kerry Wentworth, chief regulatory officer of Nuvation Bio, exercised stock options for 36,750 Class A shares at $2.93 and sold 36,750 shares at a weighted-average $5.0144. After the transactions, Wentworth holds 53,000 Nuvation Bio Class A common shares directly.

How many Nuvation Bio (NUVB) shares did Kerry Wentworth sell and at what price?

Kerry Wentworth sold 36,750 Nuvation Bio Class A common shares in open-market transactions at a weighted-average price of $5.0144 per share. The shares were sold in a price range between $5.00 and $5.05, according to the Form 4 disclosure and accompanying footnote.

How many Nuvation Bio (NUVB) shares does Kerry Wentworth own after this Form 4?

Following the reported transactions, Kerry Wentworth directly owns 53,000 shares of Nuvation Bio Class A common stock. This figure reflects holdings after exercising 36,750 stock options and selling 36,750 shares in open-market trades disclosed in the Form 4 filing.

What stock options did Kerry Wentworth exercise in Nuvation Bio (NUVB)?

Wentworth exercised stock options covering 36,750 underlying Class A common shares at a $2.93 exercise price. The option, expiring August 28, 2032, vests 25% on the one-year anniversary of August 29, 2022, with additional vesting monthly over the following 36 months.

What price range did Nuvation Bio (NUVB) shares trade at in Wentworth’s Form 4 sale?

The Form 4 notes that the 36,750 Nuvation Bio shares were sold at prices ranging from $5.00 to $5.05 per share, with a reported weighted-average sales price of $5.0144. Detailed per-price share counts are available from the reporting person upon request.